Asusi, Myca T.
HRN: 16-99-27 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/01/2023
AMPICILLIN 1GM (VIAL)
07/01/2023
07/07/2023
IV
850 Mg
Q6H
ATP
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes